Dexcom's Over Owned Position Means There's Still a Fear of Over Owning

Is there ever a concern when you've got something with so much institutional sponsorship that, uh, is there a level of when that becomes too much? I mean, not really because in, in, if I'm dealing with a stock that has 1500, 2000 funds or more that, that own it, I'm going to make sure that the fundamentals are there. The company is still delivering strong, uh, top line growth. And, uh, again, those annual estimates,  still point to a compelling growth story.